BMY's Orencia Scores Another FDA Nod, Janssen Ends Deal With CAPR, PBYI On Track

Today's Daily Dose brings you news about termination of the Collaboration Agreement and License Option entered into between Capricor and Janssen Biotech; Puma's progress in NALA trial; FDA clearance of K2M Group's NILE Proximal Fixation Spinal System; Egalet's public offering and label expansion of Bristol-Myers' rheumatoid arthritis drug Orencia.

from RTT - Biotech http://ift.tt/2sT5Zcm
via IFTTT